Antibody Information
General Information of This Antibody
Antibody ID | ANI0VKUVS |
|||||
---|---|---|---|---|---|---|
Antibody Name | Anti-SLITRK6 mAb Ha15-10ac14 |
|||||
Antibody Type | Monoclonal antibody (mAb) |
|||||
Antibody Subtype | Humanized IgG2-kappa |
|||||
Antigen Name | SLIT and NTRK-like protein 6 (SLITRK6) |
Antigen Info |
Each Antibody-drug Conjugate Related to This Antibody
Full Information of The Activity Data of The ADC(s) Related to This Antibody
HA15-10AC14F [Investigative]
Discovered Using Cell Line-derived Xenograft Model
Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 64.30% (Day 30) | High SLITRK6 expression (SLITRK6+++; IHC H-score=280) | ||
Method Description |
CDX models were established by subcutaneous injection of between 2 and 10 million SW780, RT4 (ATCC) or NCI-H322M (NCI) cells in SCID mice. When the tumor volume reached approximately 230 mm3, a single dose of Ha15-10ac14F, 5 mg/kg intravenously, was administered intravenously (iv) to the mice.
|
||||
In Vivo Model | Bladder cancer CDX model | ||||
In Vitro Model | Bladder cancer | Bladder cancer cells | Homo sapiens |
HA15-10AC14E [Investigative]
Discovered Using Cell Line-derived Xenograft Model
Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 83.10% (Day 30) | High SLITRK6 expression (SLITRK6+++; IHC H-score=280) | ||
Method Description |
CDX models were established by subcutaneous injection of between 2 and 10 million SW780, RT4 (ATCC) or NCI-H322M (NCI) cells in SCID mice. When the tumor volume reached approximately 230 mm3, a single dose of Ha15-10ac14E, 5 mg/kg intravenously, was administered intravenously (iv) to the mice.
|
||||
In Vivo Model | Bladder cancer CDX model | ||||
In Vitro Model | Bladder cancer | Bladder cancer cells | Homo sapiens |
References
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.